Compare Cassava Sciences Inc (FLNA) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs GoPro Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while GoPro Inc trades at $0.7 (market cap $122.03M). The key difference: GoPro Inc is far larger — about 2.3× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| FLNA | GPRO | |
|---|---|---|
Market Cap | $53.14M | $122.03M |
Sector | Health | Technology |
52-Week High | $4.64 | $2.88 |
52-Week Low | $1.09 | $0.64 |
Enterprise Value | -$33.43M | $169.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
GoPro (GPRO) trades at $0.6978, down 1.86% on the day, reflecting persistent bearish sentiment amid financial distress. The stock shows a negative technical trend with recent earnings misses and declining revenues. The company is undergoing a strategic review for a potential sale or merger, with the CEO providing $20 million in financing to support operations. Valuation ratios like P/E of 4.56 and P/S of 0.18 appear low, but profitability remains deeply negative with a net income margin of -20.7% and ROE of -236.05%.
The outlook is highly speculative, hinging on the success of the strategic review; a sale could unlock value, but ongoing cash burn and competitive pressures pose significant risks. Investors face a binary outcome: potential upside from a strategic transaction versus substantial downside if the company fails to stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
